RU2016140332A - Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл) - Google Patents

Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл) Download PDF

Info

Publication number
RU2016140332A
RU2016140332A RU2016140332A RU2016140332A RU2016140332A RU 2016140332 A RU2016140332 A RU 2016140332A RU 2016140332 A RU2016140332 A RU 2016140332A RU 2016140332 A RU2016140332 A RU 2016140332A RU 2016140332 A RU2016140332 A RU 2016140332A
Authority
RU
Russia
Prior art keywords
seq
polypeptide
amino acid
acid sequence
yaraaarqarakalarqlgvaa
Prior art date
Application number
RU2016140332A
Other languages
English (en)
Russian (ru)
Other versions
RU2016140332A3 (enExample
Inventor
Колин БРОФИ
Синтия ЛЭНДЕР
Пол В. НОУБЛ
Original Assignee
Мори Матрикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мори Матрикс, Инк. filed Critical Мори Матрикс, Инк.
Publication of RU2016140332A publication Critical patent/RU2016140332A/ru
Publication of RU2016140332A3 publication Critical patent/RU2016140332A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
RU2016140332A 2014-03-14 2015-03-12 Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл) RU2016140332A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953438P 2014-03-14 2014-03-14
US61/953,438 2014-03-14
PCT/US2015/020263 WO2015138784A2 (en) 2014-03-14 2015-03-12 Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf)

Publications (2)

Publication Number Publication Date
RU2016140332A true RU2016140332A (ru) 2018-04-16
RU2016140332A3 RU2016140332A3 (enExample) 2018-10-11

Family

ID=54067793

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016140332A RU2016140332A (ru) 2014-03-14 2015-03-12 Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл)

Country Status (12)

Country Link
US (1) US20150258192A1 (enExample)
EP (1) EP3116543A4 (enExample)
JP (1) JP6655547B2 (enExample)
KR (1) KR20160124236A (enExample)
CN (1) CN106456758A (enExample)
AU (1) AU2015229251A1 (enExample)
BR (1) BR112016021000A2 (enExample)
CA (1) CA2942517A1 (enExample)
MX (1) MX2016011852A (enExample)
RU (1) RU2016140332A (enExample)
SG (1) SG11201607627RA (enExample)
WO (1) WO2015138784A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3352792B1 (en) * 2015-09-25 2020-08-26 Cedars-Sinai Medical Center Targeting fibroblast invasion for pulmonary fibrosis
WO2019070908A1 (en) 2017-10-03 2019-04-11 Cedars-Sinai Medical Center METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS
CN113906132B (zh) * 2019-05-30 2024-06-28 北京生命科学研究所 特发性肺纤维化的动物模型、其构建方法和用途
KR20230044446A (ko) * 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
WO2022147172A1 (en) * 2020-12-30 2022-07-07 Briotech, Inc. Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1727564A1 (en) * 2004-03-17 2006-12-06 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
WO2012142238A2 (en) * 2011-04-12 2012-10-18 Duke University Compositions and methods for the treatment of tissue fibrosis
ES2711670T3 (es) * 2011-04-12 2019-05-06 Moerae Matrix Inc Composiciones y métodos para la prevención o tratamiento de la fibrosis pulmonar

Also Published As

Publication number Publication date
RU2016140332A3 (enExample) 2018-10-11
US20150258192A1 (en) 2015-09-17
SG11201607627RA (en) 2016-10-28
CN106456758A (zh) 2017-02-22
WO2015138784A2 (en) 2015-09-17
KR20160124236A (ko) 2016-10-26
BR112016021000A2 (pt) 2017-10-03
EP3116543A2 (en) 2017-01-18
EP3116543A4 (en) 2017-09-06
CA2942517A1 (en) 2015-09-17
JP2017509633A (ja) 2017-04-06
JP6655547B2 (ja) 2020-02-26
AU2015229251A1 (en) 2016-09-22
WO2015138784A3 (en) 2015-10-29
MX2016011852A (es) 2017-05-09

Similar Documents

Publication Publication Date Title
RU2016140332A (ru) Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл)
Li et al. Customized platelet-rich plasma with transforming growth factor β1 neutralization antibody to reduce fibrosis in skeletal muscle
RU2013150249A (ru) Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса
JP2014533235A5 (enExample)
JP2017509633A5 (enExample)
JP2016516016A5 (enExample)
PH12013501397A1 (en) Ligands that bind tgf-beta receptor ii
RU2015128496A (ru) Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
RU2017121090A (ru) Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса
Vranova et al. Lymphatic vessels in inflammation
RU2017128296A (ru) Композиция для лечения бесплодия
HK1253373A1 (zh) 使用替米沙坦预防和治疗移植物抗宿主病及其他同种免疫性和自体免疫性疾病
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
RU2017110093A (ru) Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса
EP3541402B1 (en) C3a receptor agonists for use against ischemic brain injury
JP2017528454A5 (enExample)
MX2015016143A (es) Peptidos de angiotensina para tratar el sindrome de marfan y transtornos relacionados.
Kotani et al. Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications
EP3506925B1 (en) Use of cgrp receptor antagonists in treating glaucoma
WO2013096912A3 (en) Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
Ebihara et al. Expression and function of fibroblast growth factor-inducible 14 in human corneal myofibroblasts
EP4541367A3 (en) Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
Huang et al. ID: 116: ADNIBISTRATION OF SPHINGOSINE KINASE 1 INHIBITOR POST-BLEOMYCIN CHALLENGE ATTENUATES BLEOMYCIN-INDUCED PULMONARY FIBROSIS IN MICE: ROLE OF YAP1
Kim et al. Suppressive effect of PLAG on tumor progression and its synergistic therapeutic effect with ICI therapy through adenosine clearance
Senarath-Yapa et al. Cross-Talk between TGFβ1 and BMP Signaling Modulates Apoptotic Activity in Calvarial Osteoblasts and Dural Cells and Influences the Regenerative Potential of Calvarial Bones

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200805